Certara, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 48/100
What the filing says
Certara completed the May 8, 2026 divestiture of its Regulatory and Medical Writing business and reorganized into two units (MID3 and ACE). Q2 2026 continuing operations revenue was $93.3M (1% YoY growth); software revenue grew 4% to $48.8M but services declined 3% to $44.5M. Net loss from continuing operations was $6.1M vs. $1.5M profit in Q2 2025, driven by $5.7M contingent consideration remeasurement and $2.9M currency headwinds. The company completed a $100M share repurchase program and the board authorized an additional $50M buyback. Julien Perrier was appointed Chief Commercial Officer effective August 1, 2026. FY2026 guidance reaffirmed at 0–4% revenue growth for continuing operations ($367–382M) with 29–31% adjusted EBITDA margin.
Why this rating
Divestiture is material (>5% headcount reduction, ~$13M run-rate cost savings), but modest Q2 growth, margin pressure, and net loss swing offset by strong software performance and buyback confidence. Moderate trajectory impact for $1.4B market-cap company.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.